StockLLY
Eli Lilly
1176.28-0.72%live
Raydn stories
- Eli Lilly cites new comparison showing Zepbound tops Wegovy HD on weight loss
- Novo Nordisk data show semaglutide tied to lower cardiovascular risk than tirzepatide
- Novo's cagrisema beats lower-dose tirzepatide in diabetes trial, but shares fall 7.4%
- Eli Lilly Says It Captures 70% of Seniors Starting GLP-1 Drugs
- Trump extends most-favored-nation drug pricing mandate to all state Medicaid programs
- Eli Lilly's Inluriyo wins second FDA approval as combination doubles trial survival data